- $7.94bn
- $8.06bn
- $1.16bn
- 92
- 18
- 53
- 55
Annual income statement for BIO-TECHNE, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 739 | 931 | 1,106 | 1,137 | 1,159 |
| Cost of Revenue | |||||
| Gross Profit | 483 | 633 | 756 | 770 | 770 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 581 | 694 | 809 | 789 | 952 |
| Operating Profit | 157 | 237 | 297 | 348 | 207 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 276 | 148 | 301 | 339 | 186 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 229 | 140 | 263 | 285 | 168 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 229 | 140 | 272 | 285 | 168 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 229 | 140 | 272 | 285 | 168 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.42 | 0.92 | 1.67 | 1.48 | 1.3 |
| Dividends per Share |